benefitscanada.com·há 4 meses High-cost, weight management drugs reshaping Canada’s private drug plans: report
A new generation of ultra-high-cost therapies is reshaping benefits plan risk, while the arrival of generic glucagon-like peptide-1 receptor agonist medications is set to shift one of the largest drug
